Nightfood Subsidiary Deploys Autonomous Lab Robot in Pharmaceutical Automation Milestone
Nightfood Holdings subsidiary TechForce Robotics has deployed its first autonomous lab robot, LIM-E, under a joint agreement with Oncotelic Therapeutics, marking an expansion into pharmaceutical automation and validating its AI platform beyond hospitality.
Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has successfully completed Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. This deployment marks TechForce’s first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.
TechForce said the deployment completed the initial operational goals established under the companies’ April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows and other automation applications, while Nightfood views healthcare, life sciences and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service platform.
This milestone is significant because it demonstrates the cross-industry applicability of TechForce’s robotics technology, which was initially developed for hospitality and foodservice. By entering the highly regulated pharmaceutical sector, Nightfood positions itself to tap into a market that demands precision, consistency, and efficiency—attributes that autonomous systems can deliver. The collaboration with Oncotelic, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, provides a real-world testing ground for these systems in critical environments.
For Oncotelic, the deployment of LIM-E could streamline laboratory operations, reduce human error, and accelerate research workflows. As pharmaceutical companies increasingly adopt automation to cut costs and improve reproducibility, partnerships like this one could become more common. Nightfood’s Robotics-as-a-Service model also lowers the barrier to entry for labs that may not have the capital to purchase expensive equipment outright.
The successful Phase 1 completion sets the stage for broader deployment and deeper integration of AI-enhanced workflows. Investors and industry observers will be watching to see how this partnership evolves and whether Nightfood can capture a meaningful share of the pharmaceutical automation market. For more details, the full press release is available at https://ibn.fm/RFkfL.
Nightfood Holdings, through its TechForce Robotics platform, focuses on the development, integration, and deployment of AI-enhanced automation solutions across multiple commercial industries. The company combines advanced hardware, intelligent AI-enhanced software, and scalable operational infrastructure to support long-term growth through its Robotics-as-a-Service (RaaS) model. More information is available at www.nightfoodholdings.com.